ISIS Pharmaceuticals (ISIS) Higher Following Negative Pfizer News

ISIS Pharmaceuticals Inc. (Nasdaq: ISIS) is 11% higher in pre-open action following negative new from Pfizer Inc. (NYSE: PFE) on its experimental cholesterol drug. ISIS is developing alternative cholesterol lowering drugs and some are saying it could be a takeover target.